Literature DB >> 22006780

Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007.

Amy Y Chen1, Stacey Fedewa, Jason Zhu.   

Abstract

OBJECTIVE: To describe trends and 4-year survival rate of surgical and nonsurgical treatment for laryngeal cancer.
DESIGN: Observational cross-sectional study. PATIENTS: A total of 131 694 cases of laryngeal cancer diagnosed from 1985 to 2007 identified from the National Cancer Database. MAIN OUTCOME MEASURES: Primary treatment information, including radiation therapy (RT), chemoradiation (CRT), and curative intent surgery, were identified. The association between treatment and the patient's clinical and nonclinical variables was analyzed using univariate and multivariate statistics. The 4-year survival rate was generated through Kaplan-Meier estimates, and multivariate Cox proportional hazard models were used to generate hazard ratios.
RESULTS: Among patients with early-stage cancer, the proportion receiving primary surgery increased (from 20% in 1985 to 33% in 2007), whereas the use of RT decreased from 64% to 52%. Patients with early-stage cancer who resided in areas with higher socioeconomic status (SES) zip codes, had private insurance, who were not African American, and who were treated at academic facilities were more likely to receive surgery. The 4-year survival rate for patients with early-stage laryngeal cancer treated with surgery was higher than the rate for those treated with RT (79% vs 71%). Among patients with advanced-stage cancer, the use of CRT increased from less than 7% to 45%, whereas the use of total laryngectomy decreased from 42% to 32%. The use of CRT was more common among patients who resided in areas with higher SES zip codes, had private insurance, and who were younger. The 4-year survival rates for patients with advanced laryngeal cancer treated with total laryngectomy, CRT, and RT were 51%, 48%, and 38%, respectively. Factors associated with an increased risk of death from advanced laryngeal cancer included receiving CRT and race/ethnicity.
CONCLUSIONS: Among patients with early-stage laryngeal cancer, we observed an increasing proportion of primary surgical therapy during this study period. Among patients with advanced-stage cancer, we observed an increasing proportion of CRT. Not only were clinical factors associated with type of treatment, but select sociodemographic elements were also associated with treatment. Further investigation as to the decision-making process of patients with different sociodemographic backgrounds will assist in mitigating the differences in survival for this group of patients.

Entities:  

Mesh:

Year:  2011        PMID: 22006780     DOI: 10.1001/archoto.2011.171

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  34 in total

Review 1.  Voice outcomes following radiation versus laser microsurgery for T1 glottic carcinoma: systematic review and meta-analysis.

Authors:  Matthew T Greulich; Noah P Parker; Philip Lee; Albert L Merati; Stephanie Misono
Journal:  Otolaryngol Head Neck Surg       Date:  2015-04-02       Impact factor: 3.497

2.  Secular trends in the survival of patients with laryngeal carcinoma, 1995-2007.

Authors:  S D MacNeil; K Liu; S Z Shariff; A Thind; E Winquist; J Yoo; A Nichols; K Fung; S Hall; A X Garg
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

3.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

4.  Outcomes of salvage surgery for the oropharynx and larynx: a contemporary experience in a UK Cancer Centre.

Authors:  Ashley Hay; Ricard Simo; Gillian Hall; Selvam Tharavai; Richard Oakley; Alastair Fry; Luke Cascarini; Mary Lei; Teresa Guerro-Urbano; Jean-Pierre Jeannon
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-01-21       Impact factor: 2.503

5.  Oncologic results and quality of life in patients with T3 glottic cancer after transoral laser microsurgery.

Authors:  Pei-Ju Chien; Li-Ting Hung; Ling-Wei Wang; Muh-Hwa Yang; Pen-Yuan Chu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-06       Impact factor: 2.503

Review 6.  Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature.

Authors:  Narayana Subramaniam; Deepak Balasubramanian; Rithvik Reddy; Krishnakumar Thankappan; Subramania Iyer
Journal:  Indian J Surg Oncol       Date:  2018-12-01

7.  Modifications in the treatment of advanced laryngeal cancer throughout the last 30 years.

Authors:  Jacinto García Lorenzo; Victoria Montoro Martínez; Antonio Rigo Quera; Alberto Codina Aroca; Montserrat López Vilas; Miquel Quer Agustí; Xavier León Vintró
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-17       Impact factor: 2.503

8.  Survival of patients with subglottic squamous cell carcinoma.

Authors:  S D MacNeil; K Patel; K Liu; S Shariff; J Yoo; A Nichols; K Fung; A X Garg
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

9.  Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Authors:  Dan P Zandberg; Sandy Liu; Olga Goloubeva; Robert Ord; Scott E Strome; Mohan Suntharalingam; Rodney Taylor; Robert E Morales; Jeffrey S Wolf; Ann Zimrin; Joshua E Lubek; Lisa M Schumaker; Kevin J Cullen
Journal:  Head Neck       Date:  2015-06-30       Impact factor: 3.147

10.  Predictive and prognostic factors for patients with locoregionally advanced laryngeal carcinoma treated with surgical multimodality protocol.

Authors:  Gorkem Eskiizmir; Gokce Tanyeri Toker; Onur Celik; Kivanc Gunhan; Ayca Tan; Hulya Ellidokuz
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.